Juan Martín-Liberal

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma

Stefan Diem, Benjamin Kasenda, Lavinia Spain et al. · British Journal of Cancer · 2016 · 308 citations · Full text

Medicine, Clinical Sciences, Oncology +17

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

Roy S. Herbst, Hendrik‐Tobias Arkenau, Rafael Santana-Dávila et al. · The Lancet Oncology · 2019 · 275 citations · Full text

Medicine, Oncology, Pharmacology +16

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)

Hendrik‐Tobias Arkenau, Juan Martín-Liberal, Emiliano Calvo et al. · The Oncologist · 2018 · 168 citations · Full text

Medicine, Oncology, Pharmacology +17

Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report

Juan Martín-Liberal, Andrew J.S. Furness, Kroopa Joshi et al. · Cancer Immunology Immunotherapy · 2015 · 136 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +16

A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors

Marta Ligero, Alonso García-Ruiz, Cristina Viaplana et al. · Radiology · 2021 · 105 citations

Medicine, Oncology, Radiology +17